Niagen Bioscience (NAGE) has recently made a strategic acquisition of a vital set of patents from Queen’s University Belfast. This move solidifies its position as the sole proprietor of significant nicotinamide riboside (NR) and NR salt-form intellectual property. The acquisition includes global rights and covers essential patents in composition, manufacturing, and commercialization. Following this development, Niagen has revised its revenue growth outlook to 25%-30% for 2025. Additionally, the company reported a GAAP EPS of $0.06, surpassing expectations by $0.04, and a revenue of $34 million, exceeding forecasts by $2.9 million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.